Chinese inhibitor drug candidate becomes first to enter phase
Time:2024-04-30 15:20:27 Source:travelViews(143)
Chinese biotech company Jacobio Pharma announced on Monday that it had received approval from Chinese regulatory authorities for the registration phase-3 clinical trial of a combination therapy using its SHP2 inhibitor drug candidate JAB-3312.
SHP2 inhibitors are expected worldwide to have a substantial clinical effect in cancer and immunity disease treatment, and the approval made JAB-3312 the first SHP2 inhibitor to enter the phase-3 clinical study globally.
The approved clinical study in China is designed to evaluate the efficacy and safety of JAB-3312 in combination with the company's other investigational drug candidate KRAS G12C inhibitor glecirasib, for treating first-line non-small cell lung cancer patients with KRAS G12C mutations.
The control arm is the current standard treatment for first-line non-small cell lung cancer, which is the combination therapy of PD-1 antibody and chemotherapy.
Previous:FAU's Vladislav Goldin to join Dusty May at Michigan, pulls name out of NBA draft
Next:Egyptian, Chinese students mark UN Chinese Language Day in Cairo
You may also like
- 2 policemen killed, 1 injured in 'terror' attack in SE Iran
- FIRST LOOK: As Laura Ashley relaunches, how does it stack up against its vintage heyday?
- JULIE BURCHILL: Why I spread rumours about Kate
- Australian pilot kidnapped in Papua New Guinea's highlands
- Popular Chinese crosstalk comedians bring laughter, cultural charisma to London
- Food writer baffles This Morning viewers with tips for cheap lunches
- Masterful meals: Pea and white truffle soup with Parmesan galettes
- The name's Johnson... Taylor
- Billy Joel serenades ex